Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceuticals development and commercialisation.
Blue Earth Diagnostics is funded by Syncona LLP, a subsidiary of the Wellcome Trust, the second largest philanthropic, not-for-profit healthcare foundation in the world.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
BURLINGTON, Mass. and OXFORD, UK, June 6, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that several presentations related to fluciclovine F 18 injection will...
Read More ›Saint-Genis-Pouilly, France and Oxford, UK – May 30, 2017 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine, and Blue Earth Diagnostics Ltd., a...
Read More ›OXFORD, UK. – May 23, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, announced today that the European Commission has granted marketing authorisation for Axumin™ (fluciclovine (18F))...
Read More ›– Study evaluates clinical utility of fluciclovine (18F) PET/CT imaging in men with recurrent prostate cancer following prior treatment – OXFORD, U.K. and BURLINGTON, Mass. – May 12, 2017...
Read More ›